HPLC vs Mass Spectrometry: What Each Analytical Method Actually Proves

A certificate of analysis is a document that answers questions. The useful skill is knowing which questions were actually asked. Two assays dominate peptide characterisation, and they are frequently regarded as interchangeable proof of quality. They are not. High-performance liquid chromatography and mass spectrometry interrogate different properties of the same vial, and a release record built on only one of them leaves a structural gap in what has been demonstrated.

Chromatography answers a question about proportion

High-performance liquid chromatography separates a mixture by pushing it through a packed column under pressure. Components travel at different rates depending on how strongly they interact with the stationary phase. For peptides, reversed-phase HPLC is the standard configuration: hydrophobic interaction governs retention, and a solvent gradient elutes compounds in sequence. A detector at the column outlet registers each eluting species as a peak, and the area under each peak, expressed against the total integrated area, produces the percentage figure that most people mean when they ask what HPLC testing reports.

That figure is a statement about proportion. It says the dominant peak accounts for a given share of what the detector saw. It does not say what that peak is. A chromatogram cannot distinguish the intended sequence from a closely related impurity that happens to share retention behaviour — a deletion sequence missing one residue, a diastereomer, an oxidised variant. Co-elution is a known limitation, described at length in the peptide analytical literature. Reviews in the chromatography literature have examined co-elution of synthesis-related impurities in reversed-phase separations at length, and general chapters in the European Pharmacopoeia and the United States Pharmacopeia both describe chromatographic purity as necessary and explicitly insufficient on its own.

Mass spectrometry answers a question about identity

Mass spectrometry takes a different approach entirely. The sample is ionised — electrospray ionisation is near-universal for peptides, as it transfers large biomolecules into the gas phase without fragmenting them — and the resulting ions are sorted by mass-to-charge ratio. The instrument returns a measured molecular mass. That value is compared against the theoretical mass calculated from the declared amino acid sequence. Agreement within instrument tolerance is the core of mass spectrometric identity confirmation, as described in the foundational electrospray work of Fenn and colleagues published in Science in 1989.

High-resolution instruments narrow the tolerance considerably. Time-of-flight and Orbitrap analysers resolve masses finely enough to discriminate between species that a nominal-mass instrument would report as identical. Tandem configurations go further: a selected precursor ion is fragmented, and the resulting fragment pattern is read as partial sequence information. Methodology published in the Journal of the American Society for Mass Spectrometry describes this as the practical standard for confirming that a synthesised chain matches its intended sequence rather than merely its intended weight.

Why the pairing is not redundant

The complementarity is straightforward once the questions are separated. Mass spectrometry confirms that the correct molecule is present. The published literature notes it is poor at quantifying how much of the sample that molecule represents, because ionisation efficiency varies between species and peak intensity does not map cleanly onto abundance. Chromatography quantifies reliably but identifies poorly. Neither method covers the other's blind spot, a point analytical chemistry reviews have made consistently for decades.

This is why the HPLC versus mass spectrometry framing is a false choice. Contemporary peptide purity testing methods pair them, often physically — LC-MS couples a chromatographic separation directly to a mass analyser, so each resolved peak carries its own mass assignment. Published method papers describe how a minor peak can then be characterised rather than merely counted, with an impurity provisionally identified as a truncation product or an oxidation artefact instead of logged as an anonymous fraction of the total.

Reading a release record critically

A credible analytical package shows the raw evidence, not a summary of it. That means the chromatogram itself, with a visible baseline, an identified gradient, and integration marks that can be inspected. It means the mass spectrum, with the observed value and the theoretical value stated side by side. Regulatory guidance on analytical method validation makes the same point in formal language. A single number on a letterhead, absent the underlying trace, asserts a conclusion without showing the work. The distinction between asserted and demonstrated is the entire point of the exercise.